Tempest Therapeutics (TPST) Preferred Stock Liabilities (2011 - 2020)

Tempest Therapeutics has disclosed Preferred Stock Liabilities across 4 years of filings, most recently posting $86.7 million for Q4 2020.

• In Q4 2020, Preferred Stock Liabilities changed N/A year-over-year to $86.7 million; the TTM figure through Dec 2020 stood at $86.7 million (changed N/A YoY), while the FY2020 annual figure was $86.7 million, changed N/A from the prior year.
• Preferred Stock Liabilities came in at $86.7 million for Q4 2020 at Tempest Therapeutics, roughly flat from $86.7 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $86.7 million in Q3 2020 to a low of $139000.0 in Q4 2017.